Gabriella Miller Kids First Research Act 2.0

Hozzl · 2024-03-13T11:47:45Z

Explore the details of Senate Bill 1624 Gabriella Miller Kids First Research Act 2.0 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

3/13/2024, 11:47 AM

Summary of Bill S 1624

The Bill 118 s 1624, also known as the Gabriella Miller Kids First Research Act 2.0, is a piece of legislation introduced in the US Congress. This bill aims to prioritize funding for pediatric medical research through the National Institutes of Health (NIH).

The bill is named after Gabriella Miller, a young girl who passed away from cancer at the age of 10. It seeks to honor her memory by increasing funding for research into childhood diseases and conditions.

Specifically, the Gabriella Miller Kids First Research Act 2.0 allocates $50 million annually for the next 10 years to the NIH Common Fund for pediatric research. This funding will support research on a wide range of pediatric health issues, including cancer, rare diseases, and other conditions that affect children. The bill also establishes a Pediatric Research Initiative Fund, which will provide grants to researchers studying pediatric diseases. Additionally, it requires the NIH to report to Congress on the progress and impact of the research funded by this legislation. Overall, the Gabriella Miller Kids First Research Act 2.0 aims to prioritize and support research that will improve the health and well-being of children across the United States. It has received bipartisan support in Congress and is seen as a positive step towards advancing pediatric medical research.

Congressional Summary of S 1624

Gabriella Miller Kids First Research Act 2.0

This bill modifies funding for, and requires reporting about, a pediatric disease research initiative within the National Institutes of Health (NIH).

Currently, this initiative receives funding through FY2023 from the 10-Year Pediatric Research Initiative Fund.

This bill directs certain penalties assessed by the Securities and Exchange Commission against pharmaceutical companies for specified violations to that fund. Additionally, the NIH must prioritize pediatric research that does not duplicate existing research activities when making allocations from the fund.

The bill also requires the Department of Health and Human Services to report to Congress about the research projects funded through the initiative.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 1624

Bill S 1624 is currently in the status of Bill Introduced since May 16, 2023. Bill S 1624 was introduced during Congress 118 and was introduced to the Senate on May 16, 2023. Bill S 1624's most recent activity was Placed on Senate Legislative Calendar under General Orders. Calendar No. 224. as of October 4, 2023

Bipartisan Support of Bill S 1624

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 1624

Primary Policy Focus

Health

Potential Impact Areas

- Cancer

- Child health

- Congressional oversight

- Government trust funds

- Medical research

- National Institutes of Health (NIH)

- Research administration and funding

Alternate Title(s) of Bill S 1624

Gabriella Miller Kids First Research Act 2.0

A bill to require certain civil penalties to be transferred to a fund through which amounts are made available for the Gabriella Miller Kids First Pediatric Research Program at the National Institutes of Health, and for other purposes.